Curatis Holding AG

Curatis is a specialty pharmaceutical company based in Switzerland. “We focus on the acquisition, development and commercialisation of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland that have been developed and brought to market by third party pharmaceutical companies. Curatis has exclusive distribution rights for more than 30 different drugs in Switzerland – many of them orphan disease and specialty disease medicines. This underlines Curatis’ position in the Swiss orphan drug market. Curatis has set the goal of significantly increasing the number of third-party drugs under contract in Switzerland. In addition, Curatis aims to secure distribution rights for drugs in major European markets such as Germany, France, the UK, and Italy, reflecting a clear vision for growth and market expansion. In the medium to long term, Curatis expects to launch its own products if its development projects gain regulatory approval. Curatis expects this expansion strategy to be supported by the increased visibility and funding opportunities associated with becoming a part of a publicly listed group. Development business for orphan and specialty care disease medicines Curatis has a promising pipeline of novel speciality care and orphan drugs. Our strategy is to identify compounds for which safety and clinical efficacy data already exist, enabling faster development with lower risk and investment through to commercialization. All of Curatis’ development projects have been selected in line with this strategy: C-PTBE-01 for the treatment of peritumoral brain edema in pediatric patients – next major development step: pivotal clinical study C-AM-01 for the prevention of sev